OBJECTIVES: The evaluation of the utilisation of drugs involved in treatment of CVD, its consumption in terms of expenditures units and number of packages prescribed within 2008 -2011. METHODS: Analysed data were abstracted from State Institute for Drug Control SR and studied in accordance with financial units (€) and number of packages prescribed every year. RESULTS: The overall consumption of drugs involved in tretament of CVD in number of packages prescribed was increasing from 2008 until 2010. In 2011 very slight decrease can be seen (3,8% from 37 331 100 to 35 913 249). In terms of financial units, the consumption of drugs increased from 181 319 656,40€ in 2008 to 194 185 283,80€ in 2011(the highest). The most prescribed ATC group was C09- Renin –Angiotensin System agents (24%, with its peak in 2010 - 9076 419 packages), in financial view it represents 33% (246 521 428,70 €) of all expeditures on CVD drugs (749 777 407,30 €) . Out of this group, C09A – ACEI plain was the one most prescribed with its peak in 2008 (4 820 987 packages, 23 172 192,40€), eventhough its prescription has decreasing tendency (the lowest in 2011 only 4 064 845, 17 262 264,40€). CONCLUSIONS: Obtained data proved that despite slight decrease in the number of prescribed drugs in 2011, the financial expenditures for cardiovascular medicines increase every year. The most prescribed were C09 the Renin- Angiotensin System agents – C09A ACEI plain, but the expenses had a decreasing tendency. According to this study, there is no continual proportion between amount of prescribed medicine and the amount of expenses on CVD.